Oncopia Therapeutics Inc. has patented proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a CREB-binding protein (CREBBP; CBP) and/or histone acetyltransferase KAT3B (P300)-targeting moiety through a linker.
Celgene Corp. has patented sphingosine 1-phosphate S1P5 receptor (EDG8) modulators reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis.
Bolt Biotherapeutics Inc. has designed new antibody-drug conjugates comprising humanized monoclonal antibody trastuzumab targeting HER2 covalently linked to thienoazepine derivatives acting as Toll-like receptor 7 (TLR7) and/or 8 (TLR8) agonists.
Avelos Therapeutics Inc. has discovered new substituted heterocyclic compound derivatives acting as serine/threonine-protein kinase greatwall (MASTL; GWL) inhibitors.
Several Grünenthal GmbH patents describe sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain.
Hansoh Bio LLC has described MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer, infections, neurodegeneration, autoimmune disease, immunological disorders, inflammatory conditions and cardiovascular disorders.
Denali Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord Injury, multiple sclerosis, Niemann-Pick disease, stroke, Alzheimer’s disease, amyotrophic lateral sclerosis and diabetic neuropathy, among others.
UCB SA has identified imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators reported to be useful for the treatment of inflammation and autoimmune diseases.
Recursion Pharmaceuticals Inc. has synthesized molecular glue degraders acting as RBM39 degradation inducers reported to be useful for the treatment of renal cell carcinoma.